NCT07187570View on ClinicalTrials.gov

RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,600

Participants

Timeline

Start Date

June 3, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Atrial Fibrillation (AF)
Interventions
DRUG

Dapagliflozin 10 mg once daily

Tablet Dapagliflozin 10 mg orally during from randomization for maximum 56 days.

Trial Locations (7)

11861

NOT_YET_RECRUITING

Södersjukhuset, Stockholm

14186

RECRUITING

Karolinska University Hospital, Stockholm

18527

NOT_YET_RECRUITING

Danderyds Hospital, Stockholm

58225

NOT_YET_RECRUITING

Linköping university hosptial, Linköping

70382

RECRUITING

Örebro University hospital, Örebro

75389

NOT_YET_RECRUITING

Akademiska sjukhuset, Uppsala

90185

NOT_YET_RECRUITING

Norrlands universitetssjukhus, Umeå

All Listed Sponsors
collaborator

Karolinska Institutet

OTHER

lead

Region Stockholm

OTHER_GOV